TOPLINE:

Adjuvant cemiplimab therapy reduced the risk for disease recurrence or death by 68% compared with placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy. The 24-month disease-free survival rate was 87.1% vs 64.1% with cemiplimab vs placebo.

METHODOLOGY:

The primary treatment, surgery with curative intent, achieves a cure in approximately 95% of patients. Previous trials helped identify patient subpopulations at highest risk for recurrence, but the benefit of systemic adjuvant therapy options has not been well established in clinical trials.

A phase 3, randomized trial enrolled 415 patients with local or regional cutaneous squamous cell carcinoma who completed surgery and postoperative radiotherapy, with 209 receiving cemiplimab and

See Full Page